AbbVie announced an interim analysis of an ongoing Phase III, open-label 156-week extension study evaluating the long-term safety and tolerability of oral atogepant for the prevention of migraine in participants with chronic or episodic migraine.
This guideline provides recommendations on the pharmacological management of adults with acute migraine, and prophylaxis for patients with episodic or chronic migraine or medication overuse headache.
Eli Lilly and Company announced that the National Institute for Health and Care Excellence (NICE) has recommended Emgality (galcanezumab) as an option for the prevention of migraine in adults with episodic and chronic migraine.
NuPathe Inc.has announced that the FDA has approved Zecuity (sumatriptan iontophoretic transdermal system) for the acute treatment of Migraine with...
Containing relevant Learning Zones, guidelines, trials and news.
Join Professor Mario Peres, founder of the Sao Paulo Headache Center in Sao Paulo, Brazil, in exploring emerging real-world evidence for CGRP mAbs in preventing migraine.
Purpose of review: Migraine is a primary headache disorder and one of the most common and disabling neurological diseases worldwide.
AbbVie announced at Health Canada has approved Qulipta (atogepant) for the prevention of episodic migraine (< 15 migraine days per month) in adults
Migraine is a common headache disorder characterized by often-severe headaches that may be preceded or accompanied by a variety of visual symptoms. Although a typical migraine aura is not difficult to diagnose, patients with...
Objective: This systematic review aims to show the efficiency of Erenumab in the preventive therapy of episodic and chronic migraine, which is still under research.